top of page
shutterstock_581843374.jpg

What is Glioblastoma (GBM)?

Glioblastoma (GBM) is the most diagnosed and deadliest brain tumour in adults.

Currently, there is no known cure. 

​

   DID YOU KNOW?   Glioblastoma kills more children in Australia than any other disease and more people under the age of 40 than any other cancer. Over the last decade, an average of 1,800 Australians were diagnosed with brain cancer every year.

240,000

people diagnosed globally with GBM.

​

​

95 Percent

people diagnosed die within five years with more than half having a median life span of 15 months.

30 Years

There have been limited new treatment options in over 30 years.

​

45 Percent

of malignant brain tumours are glioblastoma.

​

​

Challenges in Diagnosis and Treatment

The standard clinical trial model hinders delivering better glioblastoma treatments. It takes more than eight years, costs millions, yet offers no cure.

 

Other challenges include:
 

  • Proliferation

  • Blood-brain barriers

  • Chemoresistance

  • Varying symptoms depending on the tumour location in the brain

  • Grows and spreads rapidly

  • Invasion

​

But we are changing the way we fight brain cancer with the NEW GBM AGILE trial.

Image of patient getting scanned at the National Institute of Health.
Close up of brain scans featured on GBM AGILE trial site, discussing importance of new clinical trial in Australia.

This is a difficult and highly unpredictable cancer.

– Matthew McCarron

Close up of brain scans featured on GBM AGILE trial site, discussing importance of new clinical trial in Australia.

Be the Difference

There is a desperate need for more research to understand how GBM develops and resists treatments. GBM AGILE will help get more patients involved in clinical trials to move the best treatments forward.

​

The foundation has been set. Help ensure the future of this program by supporting GBM AGILE in Australia.

  We really want to be able to provide patients in

– Dr. Meredith Buxton
CEO of Global Coalition for Adaptive Research (GCAR)

Australia with new and better treatment options and access to investigational therapies that could be beneficial to them. Our hope is to work with the community to bring up the trial as quickly as possible.

bottom of page